10-Day Rally Sends DexCom Stock Up 9.5%
DexCom (DXCM) stock hit day 10 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 9.5% return. The company has gained about $2.3 Bil in value over the last 10 days, with its current market capitalization at about $26 Bil. The stock remains 13.1% below its value at the end of 2024. This compares with year-to-date returns of 17.1% for the S&P 500.
DexCom’s recent streak is fueled by its new G7 15-day CGM launch with enhanced Medicare coverage and the innovative Smart Basal feature for Type 2 patients. Bolstered by expanding reimbursement for non-insulin users and a strong ‘Buy’ consensus from analysts, the company’s market outlook is significantly brightening.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There is not much to fear in DXCM stock given its overall Strong operating performance and financial condition. But given its Very High valuation, the stock appears Relatively Expensive (see Buy or Sell DXCM).
For quick background, DXCM provides continuous glucose monitoring systems, including the next-generation G7 CGM, designed, developed, and commercialized for use in the U.S. and internationally.
Comparing DXCM Stock Returns With The S&P 500
The following table summarizes the return for DXCM stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | DXCM | S&P 500 |
|---|---|---|
| 1D | 1.9% | 0.7% |
| 10D (Current Streak) | 9.5% | 1.8% |
| 1M (21D) | 23.2% | 0.8% |
| 3M (63D) | -11.1% | 4.5% |
| YTD 2025 | -13.1% | 17.1% |
| 2024 | -37.3% | 23.3% |
| 2023 | 9.6% | 24.2% |
| 2022 | -15.6% | -19.4% |
However, big gains can follow sharp reversals – but how has DXCM behaved after prior drops? See DXCM Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 61 S&P constituents with 3 days or more of consecutive gains and 45 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 18 | 22 |
| 4D | 13 | 10 |
| 5D | 2 | 2 |
| 6D | 12 | 4 |
| 7D or more | 16 | 7 |
| Total >=3 D | 61 | 45 |
Key Financials for DexCom (DXCM)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $3.6 Bil | $4.0 Bil |
| Operating Income | $597.7 Mil | $600.0 Mil |
| Net Income | $541.5 Mil | $576.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $1.0 Bil | $1.2 Bil |
| Operating Income | $133.7 Mil | $212.6 Mil |
| Net Income | $105.4 Mil | $179.8 Mil |
While DXCM stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.